Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call...

Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results
Conference Call on October 30

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on
oncology, today announced that it will hold a conference call to discuss the
Company's third quarter results and provide a corporate update, including an
update on the ongoing development activities for picoplatin, the Company's
lead product candidate.
Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A.
Martell, president and chief operating officer, Caroline Loewy, chief
financial officer, and Robert De Jager, M.D., FACP, chief medical officer,
will host the call beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific
time) on Thursday, October 30. A press release for the third quarter ended
September 30, 2008, will be released after markets close on October 30.
To participate in the live call by telephone, please dial 877-419-6593
from the U.S. or 1-719-325-4885 for international callers. In addition, the
live conference call is being webcast and can be accessed on the "Events" page
of the "News & Events" section of the Company's website at
http://www.poniard.com. A replay of the webcast will be available on the
Company's website for 10 days.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the development and commercialization of innovative oncology products to
impact the lives of people with cancer. Picoplatin, the Company's lead
platform product candidate, is a new generation platinum therapy with an
improved safety profile relative to existing platinum-based cancer therapies.
Picoplatin is designed to overcome platinum resistance associated with
chemotherapy in solid tumors, and is being studied in multiple cancer
indications, combinations and formulations. Clinical trials of intravenous
picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2
trials in metastatic colorectal and hormone-refractory prostate cancers, as
well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has
not been approved by any regulatory authority for use in humans. For
additional information please visit http://www.poniard.com.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard
Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.

Brendan Doherty, Corporate Communications of Poniard Pharmaceuticals, Inc.,
+1-650-745-4425, bdoherty@poniard.com